NASDAQ:NURO NeuroMetrix (NURO) Stock Price, News & Analysis $4.50 +0.08 (+1.70%) Closing price 03:58 PM EasternExtended Trading$4.62 +0.12 (+2.76%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeuroMetrix Stock (NASDAQ:NURO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NeuroMetrix alerts:Sign Up Key Stats Today's Range$4.42▼$4.4550-Day Range$4.02▼$4.5552-Week Range$2.66▼$4.73Volume1,507 shsAverage Volume17,304 shsMarket Capitalization$9.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Read More… Remove Ads NeuroMetrix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreNURO MarketRank™: NeuroMetrix scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NeuroMetrix. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroMetrix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroMetrix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroMetrix has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NeuroMetrix's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.10% of the float of NeuroMetrix has been sold short.Short Interest Ratio / Days to CoverNeuroMetrix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroMetrix has recently decreased by 36.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroMetrix does not currently pay a dividend.Dividend GrowthNeuroMetrix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.10% of the float of NeuroMetrix has been sold short.Short Interest Ratio / Days to CoverNeuroMetrix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroMetrix has recently decreased by 36.00%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentNeuroMetrix has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for NeuroMetrix this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeuroMetrix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of NeuroMetrix is held by insiders.Percentage Held by InstitutionsOnly 19.40% of the stock of NeuroMetrix is held by institutions.Read more about NeuroMetrix's insider trading history. Receive NURO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter. Email Address NURO Stock News HeadlinesNeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.comMarch 28, 2025 | americanbankingnews.comNeuroMetrix shareholders approve merger with electroCoreMarch 27, 2025 | investing.comYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.April 3, 2025 | Premier Gold Co (Ad)NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NUROJanuary 6, 2025 | businesswire.comNeurometrix Announces Board Changes for 2024December 30, 2024 | markets.businessinsider.comNeuroMetrix announces Bradley Fluegel to resign from BoardDecember 30, 2024 | markets.businessinsider.com$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – PWOD, CARA, NURO, VOXXDecember 20, 2024 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NURO, CARA, ZUO, BMTX on Behalf of ShareholdersDecember 18, 2024 | stockhouse.comSee More Headlines NURO Stock Analysis - Frequently Asked Questions How have NURO shares performed this year? NeuroMetrix's stock was trading at $3.97 on January 1st, 2025. Since then, NURO stock has increased by 11.3% and is now trading at $4.42. View the best growth stocks for 2025 here. How were NeuroMetrix's earnings last quarter? NeuroMetrix, Inc. (NASDAQ:NURO) posted its quarterly earnings results on Tuesday, November, 5th. The medical device company reported ($0.75) EPS for the quarter. The medical device company had revenue of $0.59 million for the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 42.56% and a negative net margin of 203.71%. When did NeuroMetrix's stock split? Shares of NeuroMetrix reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of NeuroMetrix? Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroMetrix own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroMetrix investors own include AMC Entertainment (AMC), NIO (NIO), Digital World Acquisition (DWAC), Meta Platforms (META), Advanced Micro Devices (AMD), Pfizer (PFE) and Tesla (TSLA). Company Calendar Last Earnings11/05/2024Today4/03/2025Next Earnings (Estimated)4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NURO CIK1289850 Webwww.neurometrix.com Phone(781) 890-9989Fax302-636-5454Employees20Year Founded1996Profitability EPS (Most Recent Fiscal Year)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,530,000.00 Net Margins-203.71% Pretax Margin-203.69% Return on Equity-42.56% Return on Assets-39.26% Debt Debt-to-Equity RatioN/A Current Ratio13.88 Quick Ratio12.70 Sales & Book Value Annual Sales$3.77 million Price / Sales2.42 Cash FlowN/A Price / Cash FlowN/A Book Value$13.18 per share Price / Book0.34Miscellaneous Outstanding Shares2,060,000Free Float1,903,000Market Cap$9.12 million OptionableNot Optionable Beta2.15 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:NURO) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroMetrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.